Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.
Clin Chest Med. 2011 Dec;32(4):853-63. doi: 10.1016/j.ccm.2011.07.002. Epub 2011 Sep 28.
Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15%. Extensive stage disease has initial response rates to chemotherapy exceeding 70%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy backbone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development.
局限于单侧胸部的局限期小细胞肺癌采用化疗和放疗联合治疗，但长期生存率仅为 15%。广泛期疾病对化疗的初始缓解率超过 70%。然而，该疾病几乎总是会进展并导致死亡。许多最近的临床试验未能表明新型化疗药物或靶向治疗与铂类加依托泊苷的标准化疗方案相比具有优越性。许多有前途的靶向治疗药物和其他药物仍在开发中。
